Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475727 | 0.81 | PDE5A (0.64) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5473126 | 0.81 | PDE5A (0.64) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7499068 | 0.80 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5137740 | 0.78 | PDE5A (1.00) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5473149 | 0.78 | PDE5A (0.63) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5475182 | 0.78 | PDE5A (0.59) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5468890 | 0.77 | PDE5A (0.58) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4075075 | 0.76 | PDE5A (0.60) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3927280 | 0.76 | PDE5A (0.63) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4069662 | 0.76 | PDE5A (0.57) | PDE5AMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099941-A1 | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP10, CASP3, CASP4 | PDE5A 2532/4885MEN1 2882/4885KMT2A 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.